TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00846391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8245 5 mg (twice a day) b.i.d.
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8245 50 mg b.i.d.
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening.
Study: NCT02442323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: 12-week walking program
Study: NCT02598817

Intervention type: OTHER
Intervention: Standard Infant Formula
Description: Standard Infant Formula containing High Sn-2
Study: NCT00334347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote ER
Description: The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote DR
Description: The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
Study: NCT02404974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
Study: NCT03600857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home administration of misoprostol
Description: First dose of misoprostol administration at home
Study: NCT01067157

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LOGIC
Description: Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)
Study: NCT01859780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual distractor
Study: NCT04200131

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biopsy of the cyst wall with the Moray™ forceps.
Description: Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
Study: NCT02720614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation/chemotherapy
Description: Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
Study: NCT03392506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA-RTE
Description: Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
Study: NCT02673957

Intervention type: OTHER
Intervention: Blood pressure cuff protocol
Description: 4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
Study: NCT03459274

Intervention type: DEVICE
Intervention: VR-Biofeedback
Description: The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
Study: NCT03909217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TECAS Procedure
Description: Location:~1. Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~2. Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insomnia medication
Description: For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insomnia medication
Description: For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
Study: NCT03572322

Intervention type: OTHER
Intervention: Focus Group
Description: Focus Group

Intervention type: OTHER
Intervention: Interviews
Description: Interviews
Study: NCT04923152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate statin dose
Description: 5 mg rosuvastatin per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose statin
Description: 40 mg rosuvastatin per day
Study: NCT04409886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
Study: NCT03292718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyCyFAPP
Description: use of the MycyFAPP with all its features during 6 months
Study: NCT00693316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Alternating panel single dose escalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORM-12741
Description: Alternating panel single dose escalation.
Study: NCT00606970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seigen Alpha EV
Description: Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
Study: NCT00537485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: transdermal application, 1 time per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: transdermal application, 1 time per day
Study: NCT01354808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual Anti-Platelet Therapy (DAPT)
Description: * Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Anti-Platelet Therapy (TAPT)
Description: * Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month
Study: NCT03678987

Intervention type: DIAGNOSTIC_TEST
Intervention: P-MPA concentration
Description: We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA

Intervention type: DRUG
Intervention: mycophenolic acid
Description: Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
Study: NCT02880033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferiprone
Description: to test the action of deferiprone on lymphocytes from patients and controls ex vivo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferiprone
Description: to test the action of deferiprone on lymphocytes from patients and controls ex vivo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: deferiprone
Description: to test the action of deferiprone on lymphocytes from patients and controls ex vivo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: to control the action of placebo on lymphocytes from patients and controls ex vivo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: to control the action of placebo on lymphocytes from patients and controls ex vivo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: to control the action of placebo on lymphocytes from patients and controls ex vivo
Study: NCT00526032

Intervention type: PROCEDURE
Intervention: OIR Imaging
Description: Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
Study: NCT04620811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
Study: NCT02674789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: 70% VO2max bike ergometer test for 90 minutes
Study: NCT04208009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning animated videos
Description: Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
Study: NCT03739931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2752
Description: Solution for intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2752
Description: Solution for intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2752
Description: Solution for intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Solution for infusion after dilution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Solution for infusion after dilution
Study: NCT00913666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Description: 30 mcg by intramuscular injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Description: 30 mcg by intramuscular injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Description: 30 mcg by intramuscular injection once a week
Study: NCT02752321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eDischarge
Description: Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
Study: NCT02907931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care Ultrasound
Study: NCT01701596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate rotational atherectomy (RA)
Description: Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed rotational atherectomy (RA)
Description: Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
Study: NCT01756612

Intervention type: DRUG
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
Study: NCT00516451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
Study: NCT03311334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888 Dosing Emulsion
Description: DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
Study: NCT01765933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DMAA
Description: no placebo
Study: NCT02372188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: Control

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Study: NCT00429312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Thymidine kinase-deleted vaccinia virus plus GM-CSF
Study: NCT04646590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
Study: NCT02876666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Virtual Coach
Description: Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
Study: NCT03844542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
Study: NCT00872196

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Blood samples are being taken from subjects previously treated with ABT-072.
Study: NCT04459065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRDye800CW-nimotuzumab
Description: 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRDye800CW-nimotuzumab
Description: 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRDye800CW-nimotuzumab
Description: 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRDye800CW-nimotuzumab
Description: 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
Study: NCT05843513

Intervention type: OTHER
Intervention: Monitoring (observational study)
Description: The relationship between dental wear and the behaviour of the participants will be analysed.
Study: NCT03807674

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronal pulpotomy
Description: Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronal pulpotomy
Description: Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
Study: NCT04980937

Intervention type: PROCEDURE
Intervention: Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.
Study: NCT03630341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg
Description: oral 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: oral 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: 1000 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets identical to L-carnitine
Study: NCT01412099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer counseling
Description: Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback report
Description: Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback report
Description: Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
Study: NCT01522157

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat Diet
Description: Low-fat Diet is provided for a breakfast and a lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-carbohydrate Diet
Description: Low-carbohydrate Diet is provided for a breakfast and a lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Mediterranean Diet is provided for a breakfast and a lunch.
Study: NCT02949960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT210 Topical Gel
Description: DMT210 Topical Aqueous Gel 5% applied twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Topical Vehicle Gel applied twice daily
Study: NCT01306955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylorednisolone
Description: intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dextrose water 5%
Description: intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
Study: NCT04159350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal Expulsion Device (RED) - Feasibility
Description: After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal Expulsion Device (RED) - Validation
Description: After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials.
Study: NCT00626964

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.

Intervention type: BEHAVIORAL
Intervention: Conservative Treatment:
Description: Intensive Lifestyle Intervention Program